Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ADC Therapeutics (ADCT) Tax Provisions (2019 - 2025)

ADC Therapeutics has reported Tax Provisions over the past 7 years, most recently at $1.3 million for Q2 2025.

  • Quarterly results put Tax Provisions at $1.3 million for Q2 2025, up 435.9% from a year ago — trailing twelve months through Mar 2026 was $1.4 million (up 105.95% YoY), and the annual figure for FY2022 was -$1139.0, down 105.3%.
  • Tax Provisions reached $1.3 million in Q2 2025 per ADCT's latest filing, up from $165000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $1.3 million in Q2 2025 and bottomed at -$4.5 million in Q2 2023.
  • Median Tax Provisions over the past 5 years was $182500.0 (2024), compared with a mean of $29094.5.
  • The largest annual shift saw Tax Provisions tumbled 4933.33% in 2021 before it soared 1193.46% in 2022.
  • Over 5 years, Tax Provisions stood at $513479.0 in 2021, then tumbled by 100.77% to -$3967.0 in 2022, then plummeted by 2042.68% to -$85000.0 in 2023, then soared by 205.88% to $90000.0 in 2024, then skyrocketed by 1293.33% to $1.3 million in 2025.
  • Business Quant data shows Tax Provisions for ADCT at $1.3 million in Q2 2025, $165000.0 in Q1 2025, and $90000.0 in Q3 2024.